Includes all FDA approved forms and doses of Naloxone as opioid antagonists in the state definition of opioid antagonists; requires the department of health to approve all forms and doses of Naloxone approved by the FDA as opioid antagonists.
Summary
Bill A07409 amends various laws in New York to include all FDA-approved forms and doses of Naloxone in the state's definition of opioid antagonists. This change mandates that the Department of Health make available all approved formulations and dosages of Naloxone, thereby expanding access to this critical medication used to counteract opioid overdoses. The bill also allows for the purchase, distribution, and prescription of any approved formulation of Naloxone, ensuring that healthcare providers and emergency responders have the flexibility to use the most appropriate version of the drug in overdose situations.
Impact
The bill's passage would significantly impact public health law, mental hygiene law, education law, and insurance law in New York. By broadening the definition of opioid antagonists to include all FDA-approved forms of Naloxone, the bill aims to enhance the state's response to the opioid crisis. It also ensures that individuals prescribed Naloxone cannot be discriminated against in life insurance policies due to their use of opioid antagonists, thereby protecting patients' rights and promoting public health initiatives.
Sentiment
The general sentiment surrounding Bill A07409 appears to be supportive, as it addresses the urgent need for effective measures against opioid overdoses. Discussions in committee likely focused on the importance of expanding access to Naloxone, reflecting a consensus on the necessity of combating the opioid epidemic in New York. However, specific sentiments from committee discussions and voting history were not available, limiting a more detailed assessment of the bill's reception.
Contention
While the bill is largely viewed positively, potential points of contention could arise regarding the implementation of the expanded availability of Naloxone, including concerns over costs and the logistics of distribution. Stakeholders such as insurance companies may also have concerns regarding the implications of the bill on their policies and practices. However, no specific opposition has been documented in the available discussions or voting history.
Relating to measures to prevent and respond to opioid-related drug overdoses, including policies and training regarding the use of opioid antagonists, at student residences on campuses of public institutions of higher education; providing immunity.
Controlled substances: other; opioid antagonist policy; require schools to implement in certain circumstances. Amends sec. 1178 of 1976 PA 451 (MCL 380.1178) & adds sec. 1179c. TIE BAR WITH: SB 405'25
Controlled substances: other; definition of governmental agency under the administration of opioid antagonist act; modify. Amends sec. 101 of 2019 PA 39 (MCL 15.671). TIE BAR WITH: SB 404'25